Drug updated on 4/18/2024
| Dosage Form | Tablet (oral; 250 mg) |
| Drug Class | Antihelmintics |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of fascioliasis in patients 6 years of age and older.
Summary
- Triclabendazole (Egaten) is indicated for the treatment of fascioliasis in individuals aged 6 years and older. It has been evaluated for effectiveness and safety, with a particular focus on cardiac effects.
- The study was derived from a Randomized Controlled Trial.
- The study found triclabendazole to be an effective treatment for human fascioliasis, focusing on safety aspects, especially cardiac safety, without providing comparative data against other treatments.
- A significant aspect of the study was the comparison of triclabendazole's potential effect on QTc interval prolongation with that of moxifloxacin. Results suggest that triclabendazole may have a dose-dependent impact on QTc interval prolongation, posing potential risk at supratherapeutic doses but less so at therapeutic doses when compared to moxifloxacin.
- No deaths or serious adverse events were reported among participants during the study period, indicating a favorable tolerance and safety profile within this context. There were no clinically relevant abnormalities observed in laboratory evaluations or vital sign values, except for possible effects on cardiac repolarization.
- This research involved healthy individuals aged 6 years and above, providing useful information regarding the use of Egaten in such population groups. However, these findings might not fully extend to patient populations suffering from fascioliasis who are taking the medication.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Egaten (triclabendazole) Prescribing Information. | 2022 | Novartis Pharmaceuticals Corporation, East Hanover, NJ |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Effects of triclabendazole and its metabolite exposure on the heart-rate-corrected QT intervals: a randomized, placebo- and positive-controlled thorough QT study in healthy individuals. | 45Subjects F: 20% M: 80% | 2023 | Clinical and Translational Science |
Sex Distribution:
F:20%
M:80%
45Subjects
Year:
2023
Source:Clinical and Translational Science